A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 3,149,399 shares of NTLA stock, worth $45 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,149,399
Previous 3,257,689 3.32%
Holding current value
$45 Million
Previous $72.9 Million 11.23%
% of portfolio
0.05%
Previous 0.05%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$19.72 - $27.36 $2.14 Million - $2.96 Million
-108,290 Reduced 3.32%
3,149,399 $64.7 Million
Q2 2024

Jul 19, 2024

SELL
$20.02 - $27.22 $2.84 Million - $3.86 Million
-141,629 Reduced 4.17%
3,257,689 $72.9 Million
Q1 2024

Apr 19, 2024

SELL
$23.82 - $32.8 $1.89 Million - $2.6 Million
-79,244 Reduced 2.28%
3,399,318 $93.5 Million
Q4 2023

Jan 30, 2024

SELL
$23.16 - $32.34 $966,536 - $1.35 Million
-41,733 Reduced 1.19%
3,478,562 $106 Million
Q3 2023

Oct 30, 2023

BUY
$31.62 - $45.78 $3.97 Million - $5.75 Million
125,639 Added 3.7%
3,520,295 $111 Million
Q2 2023

Jul 31, 2023

BUY
$34.58 - $46.03 $9.74 Million - $13 Million
281,692 Added 9.05%
3,394,656 $138 Million
Q1 2023

Apr 27, 2023

BUY
$33.3 - $44.82 $4.56 Million - $6.14 Million
136,962 Added 4.6%
3,112,964 $116 Million
Q4 2022

Jan 30, 2023

BUY
$33.21 - $62.69 $400,977 - $756,919
12,074 Added 0.41%
2,976,002 $104 Million
Q3 2022

Oct 21, 2022

BUY
$53.92 - $71.7 $9.86 Million - $13.1 Million
182,792 Added 6.57%
2,963,928 $166 Million
Q2 2022

Jul 26, 2022

SELL
$38.49 - $76.21 $3.51 Million - $6.95 Million
-91,133 Reduced 3.17%
2,781,136 $144 Million
Q1 2022

Apr 27, 2022

BUY
$58.27 - $118.99 $6.9 Million - $14.1 Million
118,366 Added 4.3%
2,872,269 $209 Million
Q4 2021

Feb 02, 2022

BUY
$100.76 - $138.36 $35.7 Million - $49 Million
353,970 Added 14.75%
2,753,903 $326 Million
Q3 2021

Oct 25, 2021

SELL
$132.37 - $176.78 $96.3 Million - $129 Million
-727,670 Reduced 23.27%
2,399,933 $322 Million
Q2 2021

Aug 02, 2021

SELL
$60.88 - $161.91 $102 Million - $272 Million
-1,679,691 Reduced 34.94%
3,127,603 $506 Million
Q1 2021

Apr 30, 2021

SELL
$46.59 - $83.68 $13.8 Million - $24.9 Million
-297,068 Reduced 5.82%
4,807,294 $386 Million
Q4 2020

Feb 05, 2021

SELL
$18.83 - $63.53 $18 Million - $60.9 Million
-958,154 Reduced 15.8%
5,104,362 $278 Million
Q3 2020

Oct 30, 2020

SELL
$17.47 - $24.93 $2.32 Million - $3.31 Million
-132,673 Reduced 2.14%
6,062,516 $121 Million
Q2 2020

Jul 27, 2020

SELL
$11.14 - $22.87 $9.98 Million - $20.5 Million
-896,074 Reduced 12.64%
6,195,189 $130 Million
Q1 2020

Apr 27, 2020

SELL
$9.44 - $15.58 $823,706 - $1.36 Million
-87,257 Reduced 1.22%
7,091,263 $86.7 Million
Q4 2019

Jan 31, 2020

SELL
$10.43 - $17.67 $638,493 - $1.08 Million
-61,217 Reduced 0.85%
7,178,520 $105 Million
Q3 2019

Oct 31, 2019

BUY
$13.07 - $18.51 $65.7 Million - $93 Million
5,023,077 Added 226.61%
7,239,737 $96.7 Million
Q2 2019

Jul 29, 2019

BUY
$13.88 - $18.41 $16.2 Million - $21.5 Million
1,169,968 Added 111.78%
2,216,660 $36.3 Million
Q1 2019

May 08, 2019

BUY
$12.79 - $17.62 $13.4 Million - $18.4 Million
1,046,692 New
1,046,692 $17.9 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.